Nesvacumab

Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.[1] As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema.[2][3]

Nesvacumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetAngiopoietin 2
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6440H9966N1722O2008S38
Molar mass144860.89 g·mol−1

This drug is being developed by Regeneron Pharmaceuticals.

References
  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
  2. Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
  3. Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.